Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shares in Indevus Pharmaceuticals rose nearly 10% after the company announced positive results from two phase III clinical trials of its once-daily medicine for overactive bladder Sanctura XR.
Subscribe to our email newsletter
Sanctura XR is the once-daily formulation of Sanctura, which the company has marketed for overactive bladder for nearly two years.
The data from the recently completed trial showed that Sanctura XR met its primary endpoints of reduction in frequency of urination and reduction in number of urge incontinent episodes.
The trial also achieved all of its key secondary endpoints, including an increase in volume voided and a reduction in the severity of urgency, a defining symptom of overactive bladder.
In addition, the drug was extremely well tolerated and had a very low incidence of dry mouth which is a common side effect in patients treated for overactive bladder.
“We have taken a very good drug in Sanctura and, with advanced technology, made it better,” stated Dr Glenn Cooper, chairman, president and CEO of Indevus. “With Sanctura XR, I believe we have established a new benchmark in tolerability for oral drugs for the treatment of overactive bladder with a dry mouth incidence of 8.7%.”